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Clinical categorization, the classification of bacterial 
strains into susceptible, intermediate and resistant 
categories with regard to an antibiotic, is based on the 
critical values determined for minimum inhibitory 
concentrations (MICs) or for inhibition zone dia- 
meters. This classification represents the last step in the 
evaluation of a new antibiotic and should take into 
account all the information gathered during the 
appraisal. It is an essential guide for therapy [l-31. 
The antibiotic susceptibility (or resistance) of a 
strain cannot be measured directly but must be deduced 
&om the in vitro activity of the antibiotic. Among the 
various methods available, MIC determination is the 
most widely used to assess in vitro activity for clinical 
categorization of clinical isolates. To convert MIC 
values into susceptible or resistant categories, i.e., to 
assess whether it is possible to treat an infection by a 
given antibiotic, reference is made to the critical values 
recommended by national committees such as the 
Comitt de 1’Antibiogramme of the Socii‘tt FranGaise 
de Microbiologie (CA-SFM) in France, the British 
Society for Antimicrobial Chemotherapy (BSAC), or 
the National Committee for Clinical Laboratory 
Standards (NCCLS) in the USA. The values are 
established on the basis of bacteriologic, pharmaco- 
kinetic and clinical criteria [4-61. 
The differences between the critical values 
recommended by the various committees arise from 
the contrasting definitions of susceptibility and 
resistance. Two definitions of resistance have been 
proposed by the World Health Organization (WHO): 
1. A bacterial strain is considered resistant when it 
tolerates a concentration of antibiotic considerably 
higher than that which inhibits the development of 
the majority of the other strains of the same species. 
2. A bacterial strain is considered resistant when the 
concentration of antibiotic that it is able to tolerate 
is markedly higher than the concentration achiev- 
able in vivo. 
The first definition corresponds to ‘categories of 
bacterial populations’ and the second to ‘therapeutic 
categories’ on the basis of pharmacokinetic and clinical 
criteria [7-91. 
Despite these differences, it seems that a consensus 
has been reached, at least in Europe, for the 
establishment of critical values based on the three 
criteria analyzed below: 
MIC distribution of bacterial populations belong- 
ing to different species and harboring genetically 
and biochemically characterized resistance mech- 
anisms; 
pharmacokinetics, at usual and maximum dosages, 
using the different routes of administration; 
correlation between the clinical and bacteriologic 
results for the therapeutic indications assigned by 
the different ministries of health. 
BACTERIOLOGIC CRITERIA 
In the simplest case, there is a bimodal distribution of 
the MICs for bacterial strains belonging to the same 
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species that fachtates the characterization of two 
populations: one with low MICs, evenly dstributed; 
another with much higher MICs corresponding to 
strains possessing a resistance mechanism. Between these 
two populations there are few or no strains (Figure 1). 
However, and quite unfortunately, the distribution 
is often multimodal because of the multiplicity of 
resistance mechanisms. In the latter case, a larger 
number of strains is present between the limits 
separating the two main populations (Figure 2). Strain 
populations may even not be well defined (Figure 3) .  
This is, for example, generally the case for entero- 
bacteria with regard to fluoroquinolones, where some 
of the nalldix~c acid-resistant strains appear to belong to 
the drug-susceptible population. Thus, in this example, 
approximately 30% of the nalidixic acid-resistant strains 
are inhibited by concentrations of ofloxacin I 1 mg/L 
and should a priori have the same behavior in clinical 
settings as strains devoid of resistance mechanisms. 
PHARMACOKINETICS 
With regard to the relationship between the MIC 
determined in vitro and the antibiotic concentration at 
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Figure 1 
corresponding inhibition zone diameters (30-pg disks) for 
1000 strains of Staphylococcus aureus. 
Distribution of tetracycline MICs and of 
the site of infection, a strain is considered susceptible if 
its MIC is lower than the blood or tissues levels or those 
in the main pathologic center of infection following 
usual doses. The strain is considered resistant if the MIC. 
is greater than the highest concentration achievable in 
vivo. It is considered intermediate if the MIC is higher 
than blood levels and lower than levels obtained at 
certain sites of the organism or in certain fluids, in 
particular the urine and the bile. Thus, the lower 
breakpoint discriminating the susceptible and inter- 
mediate categories is based essentially on antibiotic 
serum concentrations obtained with usual doses. 
As an aid to the determination of provisional 
critical values prior to clinical studies, pharmaco- 
kinetics should provide the following information: 
Absorption: for antibiotics prescribed by the oral 
route, knowledge of the absolute biodisposibility and 
the variabhty in digestive absorption is important. 
Distribution: maximum serum concentration (CmaX) 
for a given dosage and route of administration and 
the time required to reach that peak (T,n,x); rate of 
elimination, generally assessed by determination of 
the plasma half-life (t1,2); diffusion in the humors and 
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Figure 2 
corresponding inhibition zone diameters (30-pg disks) for 
1000 strains of Kfebsiella pneunzoniae. 
Distribution of gentamicin MICs and of 
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W, nalidixic acid-resistant strains. 
Distribution of ofloxacin MICs for 850 strains of Enterobacteriaceae: 0, nalidixic acid-susceptible strains; 
tissues (keeping in mind that the values observed for 
a given antibiotic and a given tissue often vary a great 
deal depending on methodology; however, the 
results obtained can help in defining the clinical 
studies that have to be undertaken); extent of protein 
binding. 
Biotransformation: including detailed information 
on the antibacterial and pharmacokinetic properties 
of the possible metabolites. 
Elimination routes: urinary, biliary, digestive, giving 
the percentage of active form. 
The level of active drug achieved at the site of 
infection is a major factor in successful antibiotic 
therapy. The main difficulty in defining breakpoints, 
according to this observation, is that pharmacokinetic 
parameters and active concentrations at infection sites 
are usually unknown. However, most bacteria are 
located in extracellular tissue fluids and the penetration 
of the majority of antibiotics into extracellular fluids 
results in (free) drug concentrations similar to those in 
serum at steady state. The pharmacokinetics of drug in 
serum may therefore represent those in compartments 
where passive diffusion governs antibiotic penetration 
Although the actual relationship between pharm- 
acokinetic parameters and the in vitro MIC has not 
been established, some formulas taking into account 
pharmacologic and microbiological factors have been 
proposed for the calculation of breakpoints [ 5 ] .  
The following parameters related to activity are 
taken into consideration by the CA-SFM in the deter- 
mination of breakpoints [l 11: 
[lo]. 
the peak serum concentration (Cmx) achieved with 
the recommended dosage; 
the serum concentration achieved after the distribu- 
tion phase (the equilibrium is usually reached 1 h 
after administration); 
the drug half-life (tin) and the time during which 
concentration in serum exceeds the MIC; 
a restrictive or semi-restrictive protein bindmg if 
>75%. 
Following recommended dosage, either peak con- 
centration/MIC ratio above 4 to 8 or the time for 
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which plasma concentrations exceed the MIC should 
be taken into account in defining the lower breakpoint 
for drugs that, respectively, exhibit a concentration- 
dependent (e.g., aminoglycosides, fluoroquinolones) or 
a time-dependent lulling (e.g., p-lactams, glycopep- 
tides). The higher breakpoint should allow for the 
maximum serum concentration, the toxicity and the 
increased antibiotic concentration in certain sites. 
CLINICAL CRITERIA 
The clinical criteria form a necessary complement to 
those described above and provide information on the 
correlation between therapeutic success or failure and 
the proposed critical concentrations. To put it simply, 
a resistant strain escapes treatment. It is theoretically 
possible to know ifpatients infected by a bacterial strain 
with an MIC of X mg/L will recover after a usual 
treatment and if patients infected by a strain with an 
MIC hgher than Y mg/L will not recover. However, 
the results are usually debatable, since the recovery 
criteria are not always clearly defined and may differ 
depending upon the evaluation. 
The so-called ‘early clinical trial’ corresponds to 
the first therapeutic trial in humans of a new drug. This 
should include infections in which the causative 
bacterial agent belongs to the homogeneous population 
of strains with low MICs, below the low critical 
concentration proposed. ‘Only a few detailed bacterio- 
logic observations are required and may be sufficient to 
ascertain the clinical activity of a new antibiotic’ [14]. 
It ought to be possible, during the phase 111 clinical 
trials, to clarify the clinical results obtained previously 
and, in particular, to analyze the bacteriologic failures. 
These can be interpreted correctly only if one takes 
into account the dosages used, the values of the serum, 
and, if possible, humoral and tissue concentrations, 
and the MIC and resistance phenotype of the strain 
responsible for the infection. Cases of infections due to 
strains with MICs close to the lower breakpoint should 
be carefully analyzed. The critical concentrations 
proposed cannot be considered definitive unless they 
correlate with the clinical results [12]. 
Three categories of strains are classically defined 
Susceptible strains. Their MICs are attainable by 
treatment with usual doses by general routes. These 
MICs are lower than the levels achieved in the blood 
or tissues or those present in the main pathologic 
foci. 
Resistant strains. Their MICs will probably not be 
attained, irrespective of the treatment, since they are 
greater than the hghest concentrations achievable in 
vivo. 
3. Intermediate strains. Their MICs are attainable only 
with high doses of antibiotics close to toxicity, or in 
cases where local treatment is possible or physiologic 
concentrations occurs at the site of infection. 
Thus, the last category includes strains with MICs in 
the range of the concentrations achievable in vivo, i.e. 
higher than the blood levels but lower than those 
obtained in certain sites of the organism. It also includes 
strains that do not belong to the susceptible population 
but do not appear clearly resistant; certain strains may 
express a low-level resistance that could increase under 
therapy. The intermediate category also represents an 
imprecise zone, sometimes called the ‘buffer zone’, 
whch allows for technical and biological uncertainties 
~ 3 1 .  
Since it is largely based on pharmacokinetics and 
clinical criteria, the clinical categorization defines 
more closely the in vitrolin vivo parallelism. The 
size of the intermediate zone is sufficient to allow 
interpretation that takes into account concentra- 
tions at the infection site, and which is not 
dependent upon the bacterial species involved. 
The major defect in clinical categorization is that 
it relies largely on pharmacokinetic parameters that 
are sometimes difficult to define. The breakpoints 
delimiting the categories are therefore inevitably 
approximations which, while reflecting a real 
situation, make it difficult to achieve international 
standardized criteria [14]. 
RELATIONSHIP BETWEEN MlCs AND INHIBITION 
ZONE DIAMETERS 
Determination of critical diameters that delineate the 
susceptible, intermediate and resistant categories re- 
quires, for each antibiotic, a good correlation between 
the inhibition zone diameters and the corresponding 
MICs. Generally, 100 to 150 strains representative of 
the most common clinical isolates with MICs evenly 
distributed over the range studied are tested simul- 
taneously by agar dilution (MICs) and by disk df is ion 
(diameters) [ 151. The regression line between the MIC 
values (logarithm to the base 2) on the x-axis and the 
inhibition diameters (arithmetic scale) on the y-axis 
indicates the degree of correlation of the distributions 
observed. The critical diameters can then be deduced 
from the critical concentrations (Figure 4). 
In case of poor correlation, the scattergram 
obtained with several hundreds of strains collected 
during a multicenter study provides a mean for 
determination of the critical diameters. In this analysis, 
the percentage of major discrepancies, in particular Rs 
discrepancies (strain considered to be resistant by agar 
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Figure 4 
l o g  of the MIC (pg/mL) of fleroxacin determined by agar ddution (x-axis) for 649 strains. The least-squares line of 
regression (x on y) and the linear regression coefficient (r) were obtained with a Tektronix computer. 
Correlation between the idubition zone diameters (mm) obtained with a 5-pg fleroxacin disk (y-axis) and the 
dilution and susceptible by agar diffusion) is kept as low 
as possible (Figure 5) [16,17]. 
The disk-agar diffusion test is standardized for 
bacteria that grow rapidly on usual media. The 
interpretation criteria should therefore be applied 
cautiously for slow-growing bacteria or for those 
requiring supplemented medium or anaerobiosis. 
Certain resistance mechanisms, in particular due to 
detoxifying enzymes, are not always detected by the disk 
test using the standard breakpoints; special study 
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conditions and 'interpretive reading' of the results based 
on a thorough knowledge of the mechanisms of 
resistance may be required. Certain significant examples 
have been reported [ 18,191. 
CONCLUSION 
Critical values (breakpoints) for clinical categorization 
of bacterial strains with regard to a given antibiotic 
should be proposed at various stages: 
I I  
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Figure 5 Dirithromycin. Distribution of 547 clinical isolates belonging to Merent species in susceptible, intermediate and 
resistant clinical categories according to MICs (S.I.R.) and i h b i t i o n  zone diameters (s, i, r) obtained with 15-pg disks. Ss, Ii 
and R r  denote agreement; Is, Si, Ir and Ri, denote minor discrepancies; Sr and Rs denote major discrepancies. 
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Before the antibiotic is released on the market, 
provisional values can be obtained by analysis of the 
in vitro spectrum of activity, the MIC distribution of 
bacterial populations and the results of pharmaco- 
kinetics. 
More definitive values can only be established once 
authorization of release on the market has been 
granted and according to the clinical results obtained, 
the therapeutic indications and the recommended 
dosages. 
Subsequent revision of these values may occur in 
light of the information provided by monitoring 
bacterial resistance and possible modifications of the 
therapeutic indications or dosages. 
Determination of critical values is always a 
compromise that can give rise to a certain number of 
difficulties: 
0 Strains belonging to a homogeneous population 
can fall into different classes if, for pharmacokinetic 
reasons, the low breakpoint dlvides the population in 
two. Ths is one of the main reasons for introducing 
an intermediate category. 
Strains possessing a weakly expressed resistance 
mechanism that requires particular detection condi- 
tions can be considered as susceptible on the basis of 
the low breakpoint. Because of risk of clinical failure, 
decrease of this latter value or interpretive readmg of 
the susceptibility test can ensure classification of the 
strain in the intermediate or resistant category. This 
approach d, most probably, be made easier in the 
future by using artificial intelligence [20]. 
The MIC and zone diameter breakpoints recom- 
mended by the CA-SFM are provided at the end of this 
issue. 
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